Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Cholestasis

• Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis
• A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)
• Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
• Ursodeoxycholic Acid Prevents Total Parenteral Nutrition Cholestasis
• A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
• A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)
• Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
• BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases
• Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
• Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy
• An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
• MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
• Linerixibat Long-term Safety, and Tolerability Study
• Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects
• Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat
• A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
• Omegaven as Alternative Parenteral Fat Nutrition
• Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC
• Fibrates in Pediatric Cholestasis
• This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2
• Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates
• A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)
• The Effect of Aspirin on Patency of Metal Stent in Malignant Distal Bile Duct Obstruction
• Metformin in Intrahepatic Cholestasis of Pregnancy
• Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis
• A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
• Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome
• Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
• Dose-escalation Study of GSK2330672 in Japanese Healthy Male Volunteers
• Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury
• SMOFlipid to Lessen the Severity of Neonatal Cholestasis
• Effectiveness of Multicomponent Lipid Emulsion in Preterm Infants Requiring Parenteral Nutrition
• A4250, an IBAT Inhibitor in Pediatric Cholestasis
• Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants
• Compassionate Use of Omegaven IV Fat Emulsion
• Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants
• SMOF Lipid for Children With Parenteral Nutrition Induced Liver Injury
• Compassionate Use of Omegaven in Children
• Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD
• Omegaven® as Parenteral Nutrition
• Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children
• Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
• Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption
• Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis
• An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
• Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis
• An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)
• Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis
• Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis
• Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus
• Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT
• Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage
• Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury
• Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC
• Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease
• Compassionate Use of an Intravenous Fish Oil Emulsion in Infants With Cholestasis
• Preventing Cholestasis Using SMOFLipid®
• Ursodeoxycholic Acid in the Treatment of Intrahepatic Cholestasis of Pregnancy
• Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition
• Prospective Randomized Clinical Trial of Intravenous Lipids and Cholestasis
• Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury
• Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders
• Compassionate Use of Omegaven IV Fat Emulsion
• Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease
• Ursodeoxycholic Acid And Cholestasis Of Pregnancy
• Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children
• Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis
• Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation
• A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease
• Cholestasis Reversal: Efficacy of IV Fish Oil
• Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates
• Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis
• Compassionate Use of Omegaven IV Fat Emulsion
• Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants
• Cholestasis Prevention: Efficacy of IV Fish Oil
• Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
• Gabapentin to Treat Itch in Patients With Liver Disease
• Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease
• Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
• Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis
• Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants
• Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease